Stocks and Investing
Stocks and Investing
Fri, March 19, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, March 18, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Edward Nash Maintained (AKRO) at Strong Buy with Decreased Target to $46 on, Mar 18th, 2021
Edward Nash of Canaccord Genuity, Maintained "Akero Therapeutics, Inc." (AKRO) at Strong Buy with Decreased Target from $51 to $46 on, Mar 18th, 2021.
Edward has made no other calls on AKRO in the last 4 months.
There are 3 other peers that have a rating on AKRO. Out of the 3 peers that are also analyzing AKRO, 0 agree with Edward's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Edward
- Ed Arce of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $61 on, Wednesday, March 17th, 2021
- Michael Morabito of "Chardan Capital" Maintained at Strong Buy with Increased Target to $81 on, Wednesday, March 17th, 2021
- Etzer Darout of "Guggenheim" Initiated at Strong Buy and Held Target at $54 on, Friday, February 26th, 2021
Contributing Sources